2010•China Medical HeraldRequires access

Thalidomide combined with MP and VAD in the treatment of multiple myeloma for 42 cases

Guifeng Wang

Abstract

Objective: To discuss the clinical efficacy of the Thalidomide combined with MP and VAD in the patients with multiple myeloma. Methods: Clinic data of 42 patients with multiple myeloma used Thalidomide combined with MP and VAD were analyzed retrospectively. Results: 32 with multiple myeloma in first-time treatment group were given Thalidomide combined with MP, the total effective rate was 81.2%; 10 cases with multiple myeloma in relapse group were given Thalidomide combined with VAD, the total effective rate was 80.0%. Conclusion: Thalidomide combined with MP and VAD in the treatment of multiple myeloma were better than that of conventional therapy scheme (MP or VAD), and less side effects, good tolerance of patients or certain efficacy.

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Thalidomide, Medicine, Multiple myeloma, Internal medicine, Clinical efficacy, Oncology, Surgery